161 related articles for article (PubMed ID: 22023806)
21. DNA topoisomerase II is dispensable for oocyte meiotic resumption but is essential for meiotic chromosome condensation and separation in mice.
Li XM; Yu C; Wang ZW; Zhang YL; Liu XM; Zhou D; Sun QY; Fan HY
Biol Reprod; 2013 Nov; 89(5):118. PubMed ID: 24048577
[TBL] [Abstract][Full Text] [Related]
22. Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA.
Morimoto S; Tsuda M; Bunch H; Sasanuma H; Austin C; Takeda S
Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31671674
[TBL] [Abstract][Full Text] [Related]
23. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
24. DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation.
Dal Ben D; Palumbo M; Zagotto G; Capranico G; Moro S
Curr Pharm Des; 2007; 13(27):2766-80. PubMed ID: 17897022
[TBL] [Abstract][Full Text] [Related]
25. The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks.
Bombarde O; Larminat F; Gomez D; Frit P; Racca C; Gomes B; Guilbaud N; Calsou P
Mol Cancer Ther; 2017 Oct; 16(10):2166-2177. PubMed ID: 28611105
[TBL] [Abstract][Full Text] [Related]
26. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Tavian D; Silvestrini A
Curr Med Chem; 2017; 24(15):1607-1626. PubMed ID: 27978799
[TBL] [Abstract][Full Text] [Related]
28. Broken by the Cut: A Journey into the Role of Topoisomerase II in DNA Fragility.
Atkin ND; Raimer HM; Wang YH
Genes (Basel); 2019 Oct; 10(10):. PubMed ID: 31614754
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
30. Targeting DNA topoisomerase II in cancer chemotherapy.
Nitiss JL
Nat Rev Cancer; 2009 May; 9(5):338-50. PubMed ID: 19377506
[TBL] [Abstract][Full Text] [Related]
31. [Structural, mechanistic and functional insights into topoisomerase II].
Qin SY; Yuan YM; Hu X; Sun X; Su ZD
Sheng Li Xue Bao; 2016 Feb; 68(1):98-106. PubMed ID: 26915327
[TBL] [Abstract][Full Text] [Related]
32. Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology.
Ahmed SM; Dröge P
Mol Oncol; 2019 Oct; 13(10):2062-2078. PubMed ID: 31271486
[TBL] [Abstract][Full Text] [Related]
33. Myeloperoxidase inhibition protects bone marrow mononuclear cells from DNA damage induced by the TOP2 poison anti-cancer drug etoposide.
Cowell IG; Austin CA
FEBS Open Bio; 2024 Jun; 14(6):1001-1010. PubMed ID: 38531625
[TBL] [Abstract][Full Text] [Related]
34. In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines.
Binaschi M; Farinosi R; Borgnetto ME; Capranico G
Cancer Res; 2000 Jul; 60(14):3770-6. PubMed ID: 10919649
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
36. Evidence for a role of vertebrate Rad52 in the repair of topoisomerase II-mediated DNA damage.
Adachi N; Iiizumi S; Koyama H
DNA Cell Biol; 2005 Jun; 24(6):388-93. PubMed ID: 15941391
[TBL] [Abstract][Full Text] [Related]
37. DNA topoisomerase II and its growing repertoire of biological functions.
Nitiss JL
Nat Rev Cancer; 2009 May; 9(5):327-37. PubMed ID: 19377505
[TBL] [Abstract][Full Text] [Related]
38. MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner.
Shu J; Jiang J; Wang X; Yang X; Zhao G; Cai T
Cell Death Dis; 2024 Jan; 15(1):83. PubMed ID: 38263255
[TBL] [Abstract][Full Text] [Related]
39. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes.
Mao Y; Desai SD; Ting CY; Hwang J; Liu LF
J Biol Chem; 2001 Nov; 276(44):40652-8. PubMed ID: 11546768
[TBL] [Abstract][Full Text] [Related]
40. Identification of a small-molecule inhibitor of DNA topoisomerase II by proteomic profiling.
Kawatani M; Takayama H; Muroi M; Kimura S; Maekawa T; Osada H
Chem Biol; 2011 Jun; 18(6):743-51. PubMed ID: 21700210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
